Liminatus Pharma Transfers To Nasdaq Capital Market; Shares Surge In Pre-Market
Liminatus Pharma (LIMN) said its common stock moved from Nasdaq Global Market to Nasdaq Capital Market effective Aug. 4, 2026. The Nasdaq Hearings Panel granted time to regain the minimum bid price, with a compliance deadline of Sept. 3, 2026. Shares rose over 55% pre-market to about $0.16 after the transfer; last close was $0.10.
How this was made
The 30-second read
Why it matters
The Nasdaq Hearings Panel granted additional time to regain compliance, setting a Sept. 3, 2026 deadline while the stock continues trading on the Capital Market under LIMN.
Market read
A concrete exchange listing downgrade plus a specific compliance deadline can drive immediate repricing and ongoing volatility for a microcap biotech.
What to watch
Traders should monitor whether the company’s bid-price trajectory improves before Sept. 3, 2026, and whether the Capital Market status affects institutional ownership and liquidity.
Background
Liminatus Pharma (LIMN) was moved from Nasdaq Global Market to Nasdaq Capital Market effective Aug. 4, 2026, after failing the minimum bid-price requirement.
Ticker impact
Liminatus Pharma transferred from Nasdaq Global Market to Nasdaq Capital Market, with a Nasdaq Hearings Panel compliance deadline of Sept. 3, 2026.
Near-term volatility likely remains high; direction depends on whether traders view the compliance extension as a temporary reprieve versus a continued risk of delisting.
The article provides a concrete exchange action (Global to Capital) and a specific compliance deadline, which typically affects perceived listing risk and investor base.
Market effects
Microcap biopharma names with Nasdaq bid-price compliance issues may see similar risk repricing around listing status changes.
Primarily US microcap sentiment, with potential spillover to other Nasdaq Capital Market constituents.
Limited, as the event is exchange-specific and not a global macro catalyst.
Counterpoint
The compliance extension may be largely procedural, so the initial surge could fade if no fundamental catalyst (financing, trial readout, or bid-price recovery) follows.
Key entities
- companyLiminatus Pharma, Inc.
Biopharmaceutical company developing cancer therapies, subject of the Nasdaq listing transfer and compliance timeline.
- regulatorNasdaq Hearings Panel
Granted additional time to regain compliance with the minimum bid-price requirement.
- product_programIB A101
Lead program described as a humanized anti-CD47 monoclonal antibody in clinical development.
